Navigation Links
Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease
Date:7/30/2008

Findings lead to decision to start Phase III pivotal study of LY2062430 in

2009

CHICAGO, July 30 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced interim results of its Phase II study of LY2062430, an investigational anti-amyloid beta monoclonal antibody for the treatment of mild to moderate Alzheimer's disease. In this study, intravenously administered LY2062430 bound to the amyloid beta protein, resulting in increased amounts of amyloid beta in participants' blood and cerebrospinal fluid. These and other results suggest that by binding to soluble amyloid beta proteins, LY2062430 may begin to dissolve the amyloid plaques that are present in the brains of patients with Alzheimer's disease. While the precise cause of Alzheimer's disease is not known, it has been shown that people with this disorder have an excess of amyloid beta plaque in the brain, particularly in the regions associated with memory. It is theorized that decreasing the total amount of amyloid plaque and other forms of the amyloid beta protein in the brain may result in slowing of the disease progression. Importantly, LY2062430 was well tolerated with no evidence of treatment-related brain inflammation, bleeding or other side effects. The findings from this Phase II study were presented today at the Alzheimer's Association's 2008 International Conference on Alzheimer's Disease (ICAD) in Chicago.

In this randomized, controlled trial, researchers evaluated the safety and tolerability of LY2062430 administered intravenously in patients with Alzheimer's disease and in healthy volunteers. They assessed the effects of the antibody on levels of amyloid beta in the blood and cerebrospinal fluid, as an indirect measure of the effect of the antibody on amyloid beta present in the brain. Cerebrospinal fluid, which surrounds the brain and spinal cord, is thought to provide important biomarker data in addition to that obtained from
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
(Date:8/29/2014)... , Aug. 29, 2014  Pacific Medical Data ... new website design . The main website, along ... showcases the company,s new services and content relevant to ... a new streamlined design, viewers can now better understand ... health care practices and create a more visible platform ...
(Date:8/29/2014)... Research and Markets  has announced the addition of ... 2014-2018" report to their offering. ... connect, support, or surround bones. There are several types ... fascia, and other fibrous tissues. Repetitive use, accidents, injuries, ... in wear and tear in these tissues. Orthopedic soft ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3PMDS Announces New Website 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
(Date:8/31/2014)... 2014 NutriGold announces that its ... organic fruits and berries, has been approved ... tested, including purity and label claims. , ... Acid from genetically modified and chemically produced corn ... process involves the use of a genetically modified ...
(Date:8/31/2014)... 2014 Market Research Report on ... is a professional and in-depth market survey on ... report firstly reviews the basic information of Cell ... technology. , The report then explores global and ... their product specification, capacity, production value, and market ...
(Date:8/31/2014)... finds that invisible blood in urine may be an early ... for clinicians. , Scientists at the University of Exeter ... age of 60 who had invisible blood in their urine ... bladder cancer. The figure was around half those who had ... of bladder cancer. However, it was still higher than figures ...
(Date:8/31/2014)... August 31, 2014 Adults in the U.S. ... insurance coverage can now use the Quotes Pros website as ... this year can help consumers to find and compare costs ... use of the search tool this year is expected to ... different coverage plans at various price points. The strength of ...
(Date:8/31/2014)... 2014 According to an article posted in ... Times Stronger than Heroin , a new opiate has begun ... more potent than heroin. Known as acetyl fentanyl, this opiate ... many overdoses and emergency room visits among opiate addicts because ... individual might demonstrate the signs of a heroin overdose, they ...
Breaking Medicine News(10 mins):Health News:NutriGold’s Organic Wholefood-Sourced Vitamin C Gets ConsumerLab’s Seal of Approval 2Health News:NutriGold’s Organic Wholefood-Sourced Vitamin C Gets ConsumerLab’s Seal of Approval 3Health News:Cell Harvesting System Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Cell Harvesting System Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Cell Harvesting System Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Invisible blood in urine may indicate bladder cancer 2Health News:Life Insurance Quotes Tool Installed for Public Use at New Insurer Portal Website 2Health News:New Street Drug Found to be Much More Powerful Than Heroin 2Health News:New Street Drug Found to be Much More Powerful Than Heroin 3
... Brompton and Harefield NHS Trust,s Leadership Role in the Treatment ... ... Stereotaxis, Inc. (Nasdaq:,STXS) announced that British Prime Minister Gordon Brown presided ... lab at,Royal Brompton Hospital in London. The new lab features Stereotaxis ...
... Federal Rule Changes ... Tools, CHICAGO, June 24 Allscripts, the ... physicians use,to improve healthcare, announced today that it ... Hospital Presbyterian in Newport Beach,Calif. preferred pricing on ...
... Go Healthy, Inc. (Pink,Sheets: GOHE) announced today that ... based in Myakka, Florida. Under the terms of,the agreement, ... marketing and,sales related services designed to bring awareness of ... specifics outlined in the agreement,are as follows:, -- ...
... on Top Industry ... Challenges, LAS ... change, healthcare chief financial officers feel the need to,anticipate change and begin ... CFOs face daunting challenges,and their insights on the state of the industry ...
... SARASOTA, Fla., June 24 The following statement was,issued today ... no convincing evidence that early screening,detection, and treatment improve ... include potential adverse health ... and treatment side effects." Policy Statement from ...
... the open-access journal PLoS Neglected Tropical Diseases ... Asia, and Latin America are also occurring frequently among ... and children. These diseases the "neglected infections ... parasitic, bacterial, and congenital infections. , While most ...
Cached Medicine News:Health News:London's Royal Brompton Hospital Opens New Electrophysiology Lab With State of the Art Magnetic Technology to Treat Arrhythmias 2Health News:London's Royal Brompton Hospital Opens New Electrophysiology Lab With State of the Art Magnetic Technology to Treat Arrhythmias 3Health News:Hoag Memorial Hospital Presbyterian Selects Allscripts for Electronic Health Record Subsidy Program 2Health News:Hoag Memorial Hospital Presbyterian Selects Allscripts for Electronic Health Record Subsidy Program 3Health News:Go Healthy Signs Marketing Contract with AIM Marketing 2Health News:Intersection of Financial and Regulatory Forces is Broadening Roles of Healthcare CFOs 2Health News:Intersection of Financial and Regulatory Forces is Broadening Roles of Healthcare CFOs 3Health News:Diagnostic Center for Disease: Robotic Prostatectomy - A Race to Failure? 2Health News:Diagnostic Center for Disease: Robotic Prostatectomy - A Race to Failure? 3Health News:Diagnostic Center for Disease: Robotic Prostatectomy - A Race to Failure? 4Health News:'Neglected infections of poverty' in US disable hundreds of thousands of Americans annually 2
Supplied sterile in peel-open packages. Intended for one-time use....
Used for percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
Used for percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
... Olympuss extensive line of affordable, high-quality ... our high-performance light sources to provide optimal ... light weight and durable design give you ... effectively and efficiently. And each is fully-autoclavable ...
Medicine Products: